Clinical Investigation of Efficacy and Safety in Second-line Bevacizumab treatment combined with FOLFIRI or FOLFOX for metastatic colorectal cancer
Not Applicable
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000001547
- Lead Sponsor
- Tsukuba Cancer Clinical Trial Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
1)Prior bevacizumab administration 2)FOLFIRI+bevacizumab in patients with previous CPT-11-based chemotherapy, or FOLFOX+bevacizumab in patients with previous L-OHP-based chemotherapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate, Time to Treatment failure, Adverse events rate, Progression free survival, Overall survival
- Secondary Outcome Measures
Name Time Method